Genetic variations occur in many capacities and only a restricted number of DNA mutations has been implicated in cancer. With the aim to identify biomarkers that have clinical relevance, the pharmacogenomics analysis at NTRC concerns mutations that have been observed in cancer patients. Clinically actionable mutations are analysed by zooming in on independently validated hotspot mutations and copy number variations.
We can help you to identify a patient stratification marker for your compound. Cancer cell line profiling data, generally IC50 data, is used as a source of input. In case your mechanism is better represented by another parameter, e.g. Area Under the Curve, we adapt the analysis accordingly.